Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...

Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...

Regeneron acquires UK-based Oxular, adding ocular delivery technology and Phase II therapy OXU-001 for diabetic macular edema ...

Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...

One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) ...

WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed ...

China’s Innovent Biologics today announced a collaboration and exclusive license agreement with Swiss pharma giant Roche to ...

PrimeGene raises $46 million in a series B round to advance Phase III trials and regulatory filings for pumecitinib, its atopic dermatitis treatment. Funds will also support pipeline expansion and IPO ...

Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – ...